Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in September - Earnings Summary
15/12/2023 15:41
* Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a
quarterly adjusted loss of $2.09 per share for the quarter
ended in September, higher than the same quarter last year, when
the company reported EPS of $-36.74. The mean expectation of
four analysts for the quarter was for a loss of $4.09 per share.
Wall Street expected results to range from $-5.72 to $-2.60 per
share.
* Revenue fell 40.6% to $37.26 thousand from a year ago;
analysts
expected $18.67 thousand.
* Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of $2.09.
* The company reported a quarterly loss of $3.68 million.
* Sonnet Biotherapeutics Holdings Inc shares had fallen
by 45.5%
this quarter and lost 93.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $32.50
This summary was machine generated from LSEG data December 15 at
03:41 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2023 -4.09 -2.09 Beat
Jun. 30 2023 -6.82 -2.86 Beat
Mar. 31 2023 -10.89 -7.48 Beat
Dec. 31 2022 -24.20 -17.60 Beat